Sigurdsson, Martin Ingi
Kobayashi, Hirotada
Amrein, Karin
Nakahira, Kiichi
Rogers, Angela J.
Pinilla-Vera, Mayra
Baron, Rebecca M.
Fredenburgh, Laura E.
Lasky-Su, Jessica A.
Christopher, Kenneth B.
Funding for this research was provided by:
Landspitali University Hospital Science Fund (A2021-03)
Foundation for the National Institutes of Health (KL2TR002385, R01 HL152083, R01 HL142093, R01 HL114839, R01 HL123915, R01 GM115774)
Article History
Received: 20 February 2022
Accepted: 20 September 2022
First Online: 19 October 2022
Declarations
:
: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by Mass General Brigham Human Research Committee (Protocol numbers 2008P000495 and 2015P002766) and the Ethikkommission der Medizinischen Universität Graz, Austria (Ethikkommission number 21-214). Prior to the Registry of Critical Illness cohort enrollment, written informed consent was obtained which included permission for blood samples to be utilized and saved for research purposes in the future. At VITdAL-ICU trial enrollment, written informed consent was obtained, if possible, directly from the patient or from a legal surrogate. VITdAL-ICU trial consent included permission for blood specimens to be saved for future research studies.
: Not applicable.
: Dr. Amrein reports receiving lecture fees from Fresenius Kabi. Dr. Baron has served on Advisory Boards for Merck and Genentech. Drs. Sigurdsson, Kobayashi, Lasky-Su, Nakahira, Rogers, Pinilla-Vera, Baron, Fredenburgh, and Christopher report no financial or other relationships that might lead to a conflict of interest.